The results from different studies indicate that RSVL administration not only attenuates obesity-induced chronic inflammation (i.a. by attenuating the expression of proinflammatory molecules, such as IL-6, TNF-α, or interferon (IFN-γ and IFN-β)) [99,100] and inhibits OS (i.a. by decreasing malondialdehyde (MDA) and glutathione disulfide (GSSG) levels) [101] but also enhances the antioxidant capacity (i.a. by increasing the activity of liver SOD or catalase) [99,101]. The gene discussed is TNF; the disease is obesity disorder.